Clinical Trials Logo

Adrenal Hyperplasia, Congenital clinical trials

View clinical trials related to Adrenal Hyperplasia, Congenital.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03548246 Withdrawn - Clinical trials for Congenital Adrenal Hyperplasia

Androgen Reduction in Congenital Adrenal Hyperplasia

ARCH
Start date: January 2023
Phase: Phase 2
Study type: Interventional

Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height. Additionally, these children require supraphysiologic doses of hydrocortisone to suppress secretion of adrenal androgen precursors, and this treatment can retard linear growth. This study seeks to use oral abiraterone acetate (Zytiga)as an adjunct to approved CAH therapy (oral hydrocortisone and fludrocortisone) for pre-pubescent children with classic 21-hydroxylase deficiency in order to reduce daily requirement of hydrocortisone.

NCT ID: NCT03532022 Withdrawn - Clinical trials for Congenital Adrenal Hyperplasia

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

RESTORE
Start date: October 4, 2018
Phase: Phase 3
Study type: Interventional

This study is an open-label, randomised, titration-blinded, parallel arm, multicenter study to compare twice daily Chronocort® with standard care in participants with Congenital Adrenal Hyperplasia (CAH). This study will be conducted in the USA.

NCT ID: NCT02349503 Withdrawn - Clinical trials for Congenital Adrenal Hyperplasia

Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

Start date: February 2015
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multicenter, open-label, single-dose study to evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-77860 in subjects with congenital adrenal hyperplasia (CAH). The study will be conducted in approximately 15 adolescent females (12-18 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency CAH. The study will include three independent dose cohorts of NBI-77860 (approximately 5 subjects per dose cohort). Ascending doses will be evaluated as part of a sequential-cohort design.

NCT ID: NCT00485186 Withdrawn - Clinical trials for Adrenal Insufficiency

Gene Polymorphisms Influencing Steroid Synthesis and Action

Start date: June 2007
Phase: N/A
Study type: Observational

The extend of steroid biosynthesis and action is mainly dependent on underlying genetic polymorphisms and gene mutations. These sequence variations in multiple genes involved in steroid biosynthesis and action cause different diseases (for example congenital adrenal hyperplasia or disorders of sex development). In addition, sequence variations in several other genes may influence the severity of a genetically caused disease of steroid biosynthesis or action. By this, the differences in an observed phenotype may be explained. Within the study all genes necessary for adrenal and gonadal steroid biosynthesis and several genes which are known to influence the action of steroid hormones will be analysed in patients with congenital disorders of adrenal and gonadal steroid biosynthesis, disorders of steroid action and disorders of sex development. The primary aim is to set up a correlation of the disease phenotype with the different genotypes detected.